{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-23-000020","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.764847+00:00","generated_at":"2026-06-11T16:57:39.014245+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SELLAS reports Q2 net loss $8.8M; AML trials on track with IDMC meeting Q3 2023","bullets":["Net loss $8.8M ($0.31/share) vs $8.4M ($0.41/share) in Q2 2022; cash $13.8M at June 30.","Phase 3 REGAL (GPS) interim analysis expected late 2023/early 2024; IDMC meeting in Q3 2023.","Phase 2a SLS009 in AML dosed; topline data expected Q4 2023; Phase 1 safety completed.","Expects $13M milestone payments from 3D Medicines by end of Q3 2023.","R&D expenses $5.9M (up from $5.5M) driven by GPS and SLS009 trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-23-000020","json":"https://secwatch.observer/filing/0001390478-23-000020.json","markdown":"https://secwatch.observer/filing/0001390478-23-000020.md","text":"https://secwatch.observer/filing/0001390478-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/0001390478-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/sls-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T16:57:39.014245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e5819a594830a99ebd7f163a2795e34cac11fc10","claim":"SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 10, 2023, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000020/0001390478-23-000020-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}